Cuyler Luck
0000-0002-1150-0057
11 papers found
Refreshing results…
Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Figure S1-S14, Table S1-S2 & S4-S6 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Table S3 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
Mapping chromatin state and transcriptional response in CIC-DUX4 undifferentiated round cell sarcoma
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities
Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax inFLT3-andKIT-Mutant AML
Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer
Transcriptional fidelity enhances cancer cell line selection in pediatric cancers
Atypical Molecular Basis for Drug Resistance to Mitochondrial Function Inhibitors in Plasmodium falciparum
Missing publications? Search for publications with a matching author name.